- Home
- LSF vs ALXO Comparison
LSF vs ALXO Comparison
Compare LSF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | ALXO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 79.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSF | ALXO |
|---|---|---|
| Price | $2.07 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $3.30 |
| AVG Volume (30 Days) | 95.9K | ★ 255.4K |
| Earning Date | 11-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $0.40 |
| 52 Week High | $8.96 | $2.27 |
Technical Indicators
Market Signals| Indicator | LSF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 51.75 |
| Support Level | $2.13 | $1.29 |
| Resistance Level | $2.52 | $1.57 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 0.65 | 67.50 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.